Furthermore, while more clinical data are needed to further evaluate drug efficacy in patients with FOXG1 mutations, our data suggest that a trial of levodopa or tetrabenazine could be considered for the symptomatic treatment of patients with FOXG1 mutations who have prominent or disabling dystonia or dyskinesia. Here, FOXG1 is linked to Dyskinesia.